117 related articles for article (PubMed ID: 3595677)
1. Increase in cis-dichlorodiammineplatinum (II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells.
Melvik JE; Pettersen EO; Gordon PB; Seglen PO
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1523-30. PubMed ID: 3595677
[TBL] [Abstract][Full Text] [Related]
2. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.
Melvik JE; Dornish JM; Pettersen EO
Br J Cancer; 1992 Aug; 66(2):260-5. PubMed ID: 1503898
[TBL] [Abstract][Full Text] [Related]
3. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
Melvik JE; Pettersen EO
Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives.
Dornish JM; Pettersen EO
Cancer Lett; 1989 Jul; 46(1):63-8. PubMed ID: 2736510
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.
Dornish JM; Pettersen EO; Oftebro R
Br J Cancer; 1987 Sep; 56(3):273-8. PubMed ID: 3663475
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of cis-dichlorodiammineplatinum (II)-induced cytotoxicity by methylglyoxal.
Dornish JM; Pettersen EO
Anticancer Res; 1989; 9(4):1137-42. PubMed ID: 2817795
[TBL] [Abstract][Full Text] [Related]
7. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde.
Dornish JM; Pettersen EO; Oftebro R; Melvik JE
Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1287-93. PubMed ID: 6541584
[TBL] [Abstract][Full Text] [Related]
8. Effect of cis- and trans-dichlorodiammineplatinum(II) on human tumor cell proliferation in diffusion chambers in vivo.
Ambrose KR; Lowrey JS
Cancer Res; 1982 May; 42(5):1769-73. PubMed ID: 7039818
[TBL] [Abstract][Full Text] [Related]
9. Requirement of a reactive aldehyde moiety for aldehyde-mediated protection against cis-dichlorodiammineplatinum-induced cell inactivation.
Dornish JM; Pettersen EO
Biochem Pharmacol; 1990 Jan; 39(2):309-18. PubMed ID: 2302256
[TBL] [Abstract][Full Text] [Related]
10. In vitro modulating effect of the reversible protein synthesis inhibitor zilascorb (2H) on cis-diamminedichloroplatinum (II)-induced cytotoxicity.
Melvik JE; Dornish JM; Larsen RO; Børretzen B; Oftebro R; Pettersen EO
Anticancer Res; 1992; 12(1):33-8. PubMed ID: 1567178
[TBL] [Abstract][Full Text] [Related]
11. Protein accumulation in lethally damaged cells after treatment with cis-dichlorodiammineplatinum (II): lack of temporal correlation between drug effect and inhibition of spheroid volume growth.
Nordal AK; Juul NO; Pettersen EO
Anticancer Res; 1992; 12(2):305-11. PubMed ID: 1580548
[TBL] [Abstract][Full Text] [Related]
12. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde.
Dornish JM; Melvik JE; Pettersen EO
Anticancer Res; 1986; 6(4):583-8. PubMed ID: 3752939
[TBL] [Abstract][Full Text] [Related]
13. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups.
Dornish JM; Pettersen EO
Cancer Lett; 1985 Dec; 29(3):235-43. PubMed ID: 4075292
[TBL] [Abstract][Full Text] [Related]
14. Action of Cis-dichlorodiammineplatinum(II) (NSC-119875) at ehe cellular level.
Drewinko B; Gottlieb JA
Cancer Chemother Rep; 1975; 59(3):665-73. PubMed ID: 1203891
[TBL] [Abstract][Full Text] [Related]
15. Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cis-diamminedichloroplatinum(II) in human NHIK 3025 cells.
Dornish JM; Pettersen EO; Oftebro R
Cancer Res; 1989 Jul; 49(14):3917-21. PubMed ID: 2736532
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro.
Jekunen AP; Shalinsky DR; Hom DK; Albright KD; Heath D; Howell SB
Biochem Pharmacol; 1993 May; 45(10):2079-85. PubMed ID: 8512589
[TBL] [Abstract][Full Text] [Related]
17. Combination effects of cis-dichlorodiammineplatinum with selected metahalones, pyrimidine sulfoxides and pyrimidine sulfones on human NHIK 3025 cells in vitro.
Dornish JM; Undheim K; Pettersen EO; Oftebro R; Laland SG
Anticancer Drug Des; 1988 Dec; 3(3):191-8. PubMed ID: 3207466
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.
Mann SC; Andrews PA; Howell SB
Int J Cancer; 1991 Jul; 48(6):866-72. PubMed ID: 1713575
[TBL] [Abstract][Full Text] [Related]
20. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Jekunen A; Vick J; Sanga R; Chan TC; Howell SB
Cancer Res; 1992 Jul; 52(13):3566-71. PubMed ID: 1617625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
